Received Feb 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
weakness; fever; trembling; This non-serious case was reported by a consumer via call center representative and described the occurrence of weakness in a 80-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included overweight. On 08-JAN-2025, the patient received Arexvy (unknown arm) and the 1st dose of Shingrix (unknown arm). On 09-JAN-2025, 1 days after receiving Arexvy and Shingrix, the patient experienced weakness (Verbatim: weakness), fever (Verbatim: fever) and tremor (Verbatim: trembling). The patient was treated with ibuprofen. The outcome of the weakness, fever and tremor were not resolved. It was unknown if the reporter considered the weakness, fever and tremor to be related to Arexvy and Shingrix. It was unknown if the company considered the weakness, fever and tremor to be related to Arexvy and Shingrix. Additional Information: GSK Receipt Date: 09-JAN-2025 The reporter was the wife of the patient. The patient received the first dose of Shingrix and the Arexvy vaccine day before reporting. The vaccines were injected into different arms. Around noontime on the day of reporting, the patient began to experience weakness, fever (100.1 degrees Fahrenheit) and trembling. The patient took Ibuprofen to treat the fever.
Overweight
Test Date: 20250109; Test Name: Body temperature; Result Unstructured Data: (Test Result:100.1,Unit:degree F,Normal Low:,Normal High:)